Chai Discovery Secures $130 Million Series B, Advancing a New Era of Programmable Biology
Chai Discovery, an artificial intelligence–driven biotechnology company focused on molecular design, has announced a $130 million Series B funding round, marking a major milestone in its effort to reengineer how drugs are discovered and developed. The financing values Chai Discovery at $1.3 billion and was co-led by Oak HC/FT and General Catalyst. The latest round…